November 5, 2025. 8:00PM EST

Exosome Therapy 2025:

The Briefing Your Clinic Can’t Afford to Miss

Join OmniGenix and our partner Lab for a physician-level walkthrough on today’s exosome science, recent breakthroughs, sourcing standards, and plug-and-play protocols your team can implement in a cash-pay model—without adding staff, space, or new equipment.

Real Clinical Use Cases • Implementation & Protocols • Live Q&A

Exosomes & Their Scientific Breakthrough

WHO IS THIS FOR

MD/DO, NP/PA, practice owners in longevity, functional, sports med, pain, men’s health, med-spa, orthopedics.

Clinics currently using Stem Cells PRP/orthobiologics/HRT/peptides and seeking next-step biologic options.

Functional Health Professionals who see the Regenerative movement and want to know how they can become a part of it.

Operators who want cash-pay programs that don’t require capital equipment or new staff.

WHAT YOU WILL LEARN

The 2025 State of Exosomes

Cell-free signaling, cargo (mRNA/miRNA/proteins/lipids), and why delivery matters.

Safety & Sourcing Standards that Protect Your License

Single-source, pre-COVID full-term placenta origin with rigorous QC

Chain-of-custody, batch testing, documentation, and staff training basics.

Business Model & Operations

Packaging into cash-pay programs; pricing ladders; consent/admin forms

How to slot visits into your current schedule; no new rooms/equipment required

WHY OMNIGENIX

Single-Source, Pre-COVID Human Placenta: OmniGenix sources from a single, pre-COVID human placenta, ensuring unmatched biological purity, consistency, and freedom from vaccine-era cellular changes or contaminants.

OmniGenix—and our partner lab are the only manufacturer in the world operating under an FDA-cleared master cell line.

Our exosomes contain the highest levels of RNA, microRNA, proteins, and lipids ever recorded in third-party testing. These biomolecules are what gives them the power to communicate with and instruct cells to repair, modulate inflammation, and restore function.

THE COST OF WAITING

Patients already ask about exosomes—many will seek clinics that offer them

Competing practices are packaging exosomes alongside PRP/HRT/peptides in bundled programs

Early movers capture local SEO and referral momentum; late adopters play catch-up

Frequently Asked Qustions

What makes OmniGenix Exosomes the Global Leader?

OmniGenix Exosomes—manufactured by our partner lab are recognized globally as the gold standard in exosome therapy. Derived from a single-source, pre-COVID human placenta and produced under the only FDA-cleared master cell line, our exosomes deliver unmatched purity, consistency, and biological potency. Containing the highest concentrations of RNA, microRNA, proteins, and lipids ever recorded, OmniGenix Exosomes are engineered to communicate with the body at a cellular level, supporting repair, regeneration, and optimized performance like no other product in the world.

Is exosome therapy FDA-approved?

No. Exosome therapy is not FDA-approved and is not intended to diagnose, treat, cure, or prevent any disease; individual responses vary. This webinar is for educational purposes and focuses on science, safety, and lawful clinic operations.

Can I bill insurance?

Programs are positioned as cash-pay. We’ll discuss transparent pricing, documentation, and patient communication. (We do not provide billing or coding advice for third-party payers.)

Who can administer?

Within scope and state law, typically MD/DO/NP/PA; joint injections require appropriate licensure and—where indicated—ultrasound/fluoro/CT guidance.

How are products sourced and handled?

Single-source, pre-COVID full-term placenta; strict QC with batch documentation. We’ll review storage/handling and staff training checklists.

How are the profit margins with Exosome Therapy?

Exosome therapy is one of the highest-margin services in regenerative medicine today. Most clinics experience profit margins of 80% + per treatment, depending on pricing structure and delivery method. Because exosome protocols require no new staff, space, or equipment, nearly every dollar generated flows directly to the bottom line.